Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting

Insider Buying: Rapport Therapeutics Chief Financial Officer Bought US$101k Of Shares

Top Executives Make Bold Moves with Major Stock Purchases!

Rapport Therapeutics Reports 2024 Financial Results and Progress

Rapport Therapeutics Q4 2024 GAAP EPS $(0.57) Beats $(0.62) Estimate, Ended the year with $305.3M in cash, cash equivalents, and short-term investments, which is expected to fund operations through the end of 2026

Rapport Therapeutics Inc trading resumes

Rapport Therapeutics Inc trading halted, volatility trading pause

Rapport Therapeutics Appoints New CMO Amid Phase 2a Updates

Rapport Therapeutics : Intends to Initiate Additional Phase 2a Trial of Rap-219 in Bipolar Mania in Q3 2025 With Topline Data Expected in H1 of 2027

Rapport Therapeutics Announces Appointment of DR. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine Development

Press Release: Rapport Therapeutics Announces Appointment of Dr. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine Development

Rapport Therapeutics to Participate in Upcoming Investor Conferences

Rapport Therapeutics, Inc. (RAPP) Receives a Buy from Stifel Nicolaus

Promising Clinical Trial Results and Stable Leadership Secure Buy Rating for Rapport Therapeutics

Stifel Nicolaus Remains a Buy on Rapport Therapeutics, Inc. (RAPP)

Rapport Therapeutics Reports Positive Early Data for Epilepsy Drug Candidate

Rapport Therapeutics announces new Phase 1 data for RAP-219

Rapport Therapeutics Inc - Phase 2a Trial of Rap-219 on Track, Data Expected Mid-2025

Rapport Therapeutics Announces New Phase 1 Data, Further Supporting Rap-219'S Transformative Potential for CNS Disorders

Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders